TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03210038
Drug: Water
Normalized name: Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
Study: NCT01204138
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 30mg BID
Study: NCT00328627
Drug: Pioglitazone placebo
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone placebo-matching tablets.
Study: NCT01469910
Drug: Simotinib Hydrochloride
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
Study: NCT01820442
Drug: Lofexidine HCl
Normalized name: lofexidine HCl
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
Study: NCT01820442
Drug: Lofexidine-matching sugar pill
Normalized name: lofexidine Pill
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
Study: NCT00930059
Drug: PF-04447943
Normalized name: PF-04447943
DrugBank: PF-04447943 (DB11953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 25 mg every 12 hours for 12 wks
Study: NCT01984255
Drug: Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV
DrugBank: Bavituximab (DB05136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.
Study: NCT01984255
Drug: Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
Study: NCT04473417
Drug: Forxiga
Normalized name: Farxiga
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single dose administration after 10hr fasting
Study: NCT04473417
Drug: DA-2811
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration after 10hr fasting
Study: NCT04473417
Drug: DA-2811
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration after high fat and calorie fed diet
Study: NCT03908619
Drug: Omeprazole 20mg
Normalized name: OMEPRAZOLE 20MG CAP,SA
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
Study: NCT03908619
Drug: Esomeprazole 20mg
Normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
Study: NCT03908619
Drug: Rabeprazole Sodium 20mg
Normalized name: Rabeprazole Sodium 20mg Oral tablet, gastro-resistant
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
Study: NCT03908619
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
Study: NCT00606242
Drug: Fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Fluticasone, either 100 or 1000 mcg per day
Study: NCT01542645
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone (0.3 mg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
Study: NCT00453297
Drug: MF101
Normalized name: MF101
DrugBank: MF101 (DB05052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03275623
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
Study: NCT00283842
Drug: DVS SR
Normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: SRP-6004 (DB16998)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00495339
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500-1000 mg once a day daily per os with combination of drugs.
Study: NCT00320892
Drug: Atropine Sulphate 1% ophthalmic drops
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
Study: NCT04118166
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 1 mg/kg, injection
Study: NCT04118166
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3 mg/kg, injection
Study: NCT02363517
Drug: Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
Study: NCT00505843
Drug: Comparator: carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
Study: NCT00038207
Drug: Liposomal Vincristine
Normalized name: vincristine liposome
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
Study: NCT01916980
Drug: Desloratadine 5 mg
Normalized name: desloratadine 5 MG
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
Study: NCT02734069
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.
Study: NCT02324270
Drug: Diclofenac epolamine
Normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
Study: NCT00550147
Drug: Oros Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oros methylphenidate will be titrated over 3 visits according to the following schedule:~* Visit 2 dose of 18 mg QAM~* Visit 3 dose of 36mg QAM~* Visit 4 dose of 54mg QAM.
Study: NCT00550147
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~* Visit 5 dose of 25mg BID~* Visit 6 dose of 50mg BID~* Visit 7 dose of 100mg BID~* Visit 8 dose of 200mg BID~* Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule.
Study: NCT01519947
Drug: Methoxy polyethylene glycol-epoetin beta
Normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received 50-250 mcg SC according to local label
Study: NCT03797196
Drug: low dose tacrolimus in combination with everolimus
Normalized name: Everolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
Study: NCT03071770
Drug: ivosidenib (AG-120)
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
Study: NCT00161083
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01101646
Drug: rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
Study: NCT01101646
Drug: rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
Study: NCT01101646
Drug: rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
Study: NCT04013334
Drug: Nivolumab Injection [Opdivo]
Normalized name: nivolumab Injection [Opdivo]
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 480 mg by IV infusion every 4 weeks
Study: NCT01658891
Drug: combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
Study: NCT01658891
Drug: free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
Study: NCT01238679
Drug: PF-04958242
Normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00884390
Drug: moroctocog alfa (AF-CC) (ReFacto AF)
Normalized name: Moroctocog alfa
DrugBank: Moroctocog alfa (DB13999)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Providing moroctocog alfa (AF-CC) as test article for use during this study.
Study: NCT03020160
Drug: Emicizumab
Normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.
Study: NCT00999115
Drug: Expanded allogenic adipose-derived adult stem cells
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
Study: NCT01534754
Drug: Mesalazine 800 mg
Normalized name: mesalazine 800 MG Delayed Release Oral Tablet
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
Study: NCT01534754
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
Study: NCT01202253
Drug: anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
Study: NCT00294541
Drug: ICA-17043
Normalized name: ICA-105665
DrugBank: CA-170 (DB15772)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01151696
Drug: Atarax (Hydroxyzine)
Normalized name: hydroxyzine hydrochloride Oral Solution [Atarax]
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One milligram per 10 kilogram, intramuscular use
Study: NCT02254486
Drug: Trisulfate solution
Normalized name: thiosulfate
DrugBank: Gold sodium thiosulfate (DB15974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Study: NCT03324815
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain Treatment
Study: NCT03324815
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain Treatment
Study: NCT02340962
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
Study: NCT02340962
Drug: Interferon Alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5.
Study: NCT04541680
Drug: Nintedanib 150 MG [Ofev]
Normalized name: nintedanib 150 MG [Ofev]
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
Study: NCT03893799
Drug: RBT-1
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT00956189
Drug: aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
Study: NCT01178138
Drug: Prazosin
Normalized name: Prazosin
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
Study: NCT00859404
Drug: oglemilast
Normalized name: Oglemilast
DrugBank: Oglemilast (DB12375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet oglemilast or placebo once a day, for 12 weeks
Study: NCT02003391
Drug: Beta-blocker monotherapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per participant's current prescribed therapy
Study: NCT02003391
Drug: Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03727139
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rasagiline Tablets
Study: NCT01477060
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1250 mg/ die, os
Study: NCT01477060
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1500 mg/die, os
Study: NCT02115152
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00600015
Drug: Erlotinib + Placebo
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
Study: NCT00501982
Drug: Poractant alfa (Curosurf®)
Normalized name: PORACTANT ALFA
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01140607
Drug: Cabazitaxel (XRP6258)
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study: NCT01320722
Drug: Vitamin D ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50,000 unit soft gel capsule once per week for 8 weeks
Study: NCT01320722
Drug: Probenecid
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
Study: NCT01320722
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
Study: NCT01159847
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin tablet,100 mg p.o. qd,2 year
Study: NCT00555750
Drug: eszopiclone
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3mg tablet, by mouth nightly 30 min before bed, for two months
Study: NCT00822887
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
Study: NCT00731874
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed to achieve target trough concentrations.
Study: NCT00936624
Drug: montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast 10mg po, bid, 12week
Study: NCT04480281
Drug: Lidocaine Iv
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the Lidocaine group received a bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
Study: NCT03110055
Drug: Grazoprevir/Elbasvir
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anti-viral treatment for HCV
Study: NCT01159847
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03436719
Drug: Mechanical Bowel Preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beginning of MBP at 4 p.m. in a day before surgery
Study: NCT03243019
Drug: rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral administration
Study: NCT01068704
Drug: BMS-690514
Normalized name: BMS-690514
DrugBank: BMS-690514 (DB11665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 200 mg, once daily, \~ 12 months depending on response
Study: NCT01068704
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response
Study: NCT01068704
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response